NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Price, News & Analysis $2.12 +0.05 (+2.42%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$2.27 +0.15 (+7.08%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ProQR Therapeutics Stock (NASDAQ:PRQR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProQR Therapeutics alerts:Sign Up Key Stats Today's Range$2.01▼$2.1550-Day Range$1.68▼$2.4852-Week Range$1.07▼$4.62Volume172,050 shsAverage Volume216,923 shsMarket Capitalization$223.05 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Read More ProQR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScorePRQR MarketRank™: ProQR Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 1354th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about ProQR Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.31) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ProQR Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.41% of the outstanding shares of ProQR Therapeutics have been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently increased by 23.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.41% of the outstanding shares of ProQR Therapeutics have been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently increased by 23.10%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.89 News SentimentProQR Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ProQR Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PRQR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.65% of the stock of ProQR Therapeutics is held by institutions.Read more about ProQR Therapeutics' insider trading history. Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Stock News HeadlinesProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Buy" from BrokeragesJuly 30, 2025 | americanbankingnews.comProQR Announces Upcoming Presentation at RNA Editing SummitJuly 28, 2025 | globenewswire.comCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities. | Brownstone Research (Ad)ProQR Therapeutics price target raised to $5 from $4 at Evercore ISIJuly 12, 2025 | msn.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.comJuly 8, 2025 | investing.comPRQR - ProQR Therapeutics NV Sustainability - MorningstarJuly 3, 2025 | morningstar.comMPRQR - ProQR Therapeutics NV Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMProQR Therapeutics NV (PRQR) Stock Forums - Investing.comJune 29, 2025 | investing.comSee More Headlines PRQR Stock Analysis - Frequently Asked Questions How have PRQR shares performed this year? ProQR Therapeutics' stock was trading at $2.65 at the beginning of the year. Since then, PRQR stock has decreased by 20.0% and is now trading at $2.12. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics N.V. (NASDAQ:PRQR) posted its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biopharmaceutical company earned $4.89 million during the quarter, compared to the consensus estimate of $4.90 million. ProQR Therapeutics had a negative net margin of 157.04% and a negative trailing twelve-month return on equity of 53.49%. Who are ProQR Therapeutics' major shareholders? ProQR Therapeutics' top institutional shareholders include Privium Fund Management B.V. (4.75%), Platinum Investment Management Ltd. (1.38%) and Vontobel Holding Ltd. (0.06%). How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProQR Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), (BIOA) (BIOA) and Virgin Galactic (SPCE). Company Calendar Last Earnings5/08/2025Today8/06/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRQR CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Price Target for ProQR Therapeutics$8.00 High Price Target$14.00 Low Price Target$4.00 Potential Upside/Downside+277.4%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.04 million Net Margins-157.04% Pretax Margin-158.13% Return on Equity-53.49% Return on Assets-22.07% Debt Debt-to-Equity RatioN/A Current Ratio4.10 Quick Ratio4.10 Sales & Book Value Annual Sales$20.46 million Price / Sales10.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book2.33Miscellaneous Outstanding Shares105,210,000Free Float96,375,000Market Cap$223.05 million OptionableOptionable Beta0.43 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:PRQR) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.